Q2 2021 Results - Reimagining Medicine
Participants
Financial performance
Company overview
Pharmaceuticals
Oncology
Financial review
Conclusion
Appendix
References
Innovation: Pipeline overview
Innovation: Clinical trials
CRM
IHD
Neuroscience
Oncology
Ophthalmology
Respiratory
Sandoz Biopharmaceuticals
Global Health
Abbreviations
EntrestoⓇ
(ARNI)
Study
Indication
Phase
Patients
Primary Outcome
Measures
Arms Intervention
-
Angiotensin II Receptor Neprilysin Inhibitor
NCT02884206 PERSPECTIVE (CLCZ696B2320)
Heart failure
Phase 3
592
Change from baseline in the CogState Global Cognitive Composite Score (GCCS)
Sacubitril/valsartan 50, 100, and 200 mg bid with placebo of valsartan
Valsartan 40, 80, and 160 mg bid tablets with placebo for sacubitril/valsartan
Patients with chronic heart failure with preserved ejection fraction
NCT02924727 PARADISE-MI (CLCZ696G2301)
Post-acute myocardial infarction
Phase 3
5670
Time to the first occurrence of a confirmed composite endpoint (cardiovascular (CV)
death, heart failure (HF) hospitalization, or outpatient heart failure)
Sacubitril/valsartan 50 mg, 100 mg, 200 mg bid; placebo for ramipril ; placebo for
valsartan
Ramipril 1.25 mg, 2.5 mg, and 5 mg bid; placebo for sacubitril/valsartan; placebo for
valsartan
Post-AMI patients with evidence of LV systolic dysfunction and/or pulmonary
congestion, with no known prior history of chronic HF
Q2-2021 (actual)
PARADISE-MI study design / baseline characteristics: published in Q2-2021
(actual)
Data presentation at ACC Q2-2021 and plans for further scientific events
Target Patients
Read-out Milesstone(s)
2022
Publication
TBD
59 Investor Relations | Q2 2021 Results
1 NOVARTIS | Reimagining MedicineView entire presentation